GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SpringWorks Therapeutics Inc (NAS:SWTX) » Definitions » ROE %

SpringWorks Therapeutics (SpringWorks Therapeutics) ROE % : -58.57% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is SpringWorks Therapeutics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. SpringWorks Therapeutics's annualized net income for the quarter that ended in Mar. 2024 was $-349.54 Mil. SpringWorks Therapeutics's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $596.83 Mil. Therefore, SpringWorks Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 was -58.57%.

The historical rank and industry rank for SpringWorks Therapeutics's ROE % or its related term are showing as below:

SWTX' s ROE % Range Over the Past 10 Years
Min: -66.56   Med: -38.52   Max: -10.37
Current: -66.56

During the past 7 years, SpringWorks Therapeutics's highest ROE % was -10.37%. The lowest was -66.56%. And the median was -38.52%.

SWTX's ROE % is ranked worse than
64.12% of 1360 companies
in the Biotechnology industry
Industry Median: -44.015 vs SWTX: -66.56

SpringWorks Therapeutics ROE % Historical Data

The historical data trend for SpringWorks Therapeutics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SpringWorks Therapeutics ROE % Chart

SpringWorks Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -38.52 -10.37 -35.51 -56.58 -54.90

SpringWorks Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.15 -65.05 -75.09 -73.90 -58.57

Competitive Comparison of SpringWorks Therapeutics's ROE %

For the Biotechnology subindustry, SpringWorks Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SpringWorks Therapeutics's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SpringWorks Therapeutics's ROE % distribution charts can be found below:

* The bar in red indicates where SpringWorks Therapeutics's ROE % falls into.



SpringWorks Therapeutics ROE % Calculation

SpringWorks Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-325.104/( (558.192+626.219)/ 2 )
=-325.104/592.2055
=-54.90 %

SpringWorks Therapeutics's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-349.54/( (626.219+567.44)/ 2 )
=-349.54/596.8295
=-58.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


SpringWorks Therapeutics  (NAS:SWTX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-349.54/596.8295
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-349.54 / 84.024)*(84.024 / 691.31)*(691.31 / 596.8295)
=Net Margin %*Asset Turnover*Equity Multiplier
=-416 %*0.1215*1.1583
=ROA %*Equity Multiplier
=-50.54 %*1.1583
=-58.57 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-349.54/596.8295
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-349.54 / -349.54) * (-349.54 / -375.724) * (-375.724 / 84.024) * (84.024 / 691.31) * (691.31 / 596.8295)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9303 * -447.16 % * 0.1215 * 1.1583
=-58.57 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


SpringWorks Therapeutics ROE % Related Terms

Thank you for viewing the detailed overview of SpringWorks Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


SpringWorks Therapeutics (SpringWorks Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
100 Washington Boulevard, Stamford, CT, USA, 06902
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.
Executives
Tai-an Lin officer: Chief Scientific Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BOULEVARD, STAMFORD CT 06902
Julie Hambleton director C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080
Jeffrey Lawrence Schwartz director, 10 percent owner C/O BAIN CAPITAL LIFE SCIENCES, LP, 200 CLARENDON STRERET, BOSTON MA 02116
Daniel Pichl officer: Chief People Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
James Cassidy officer: Chief Medical Officer 368 NOD HILL ROAD, WILTON CT 06897
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carlos Alban director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064
Saqib Islam director, officer: Chief Executive Officer ALEXION PHARMACEUTICALS, 352 KNOTTER DRIVE, CHESHIRE CT 06410
L. Mary Smith officer: See Remarks C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902
Bain Capital Life Sciences Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Michael F. Burgess officer: Head of Research & Development C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMRIDGE MA 02142
Stephen P Squinto director, 10 percent owner C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Bhavesh Ashar officer: Chief Commercial Officer C/O SPRINGWORKS THERAPEUTICS, 100 WASHINGTON BLVD, STAMFORD CT 05902
Orbimed Capital Gp Vi Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Badreddin Edris officer: Chief Business Officer C/O SPRINGWORKS THERAPEUTICS, INC., 100 WASHINGTON BLVD., STAMFORD CT 06902

SpringWorks Therapeutics (SpringWorks Therapeutics) Headlines

From GuruFocus